[1] 中华医学会神经病学分会.中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2014[J].中华神经科杂志,2015,48(4):258-273.
[2] NAVE A H,LANGE K S,LEONARDS C O,et al.Lipoprotein(a) as a risk factor for ischemic stroke:a meta-analysis[J].Atherosclerosis,2015,242(2):496-503.
[3] BERG K.A new serum type system in man——the Lp system[J].Acta Pathol Microbiol Scand,1963,59:369-382.
[4] HOOVER-PLOW J,HUANG M.Lipoprotein(a) metabolism:potential sites for therapeutic targets[J].Metabolism,2013,62(4):479-491.
[5] KETTUNEN J,DEMIRKAN A,WURTZ P,et al.Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA[J].Nat Commun,2016,7:11122.
[6] SIEKMEIER R,SCHARNAGL H,KOSTNER G M,et al.Lipoprotein(a)-structure,epidemiology,function and diagnostics of a cardiovascular risk marker[J].Open Clinical Chemistry Journal,2008,1(1):79-91.
[7] SULTAN S M,SCHUPF N,DOWLING M M,et al.Review of lipid and lipoprotein(a) abnormalities in childhood arterial ischemic stroke[J].Int J Stroke,2014,9(1):79-87.
[8] HONG X W,WU D M,LU J,et al.Lipoprotein(a) as a predictor of early stroke recurrence in acute ischemic stroke[J].Mol Neurobiol,2016,53(1):1-9.
[9] BEHESHTIAN A,SHITOLE S G,SEGAL A Z,et al.Lipoprotein(a) level,apolipoprotein(a) size,and risk of unexplained ischemic stroke in young and middle-aged adults[J].Atherosclerosis,2016,253:47-53.
[10] EMERGING-RISK-FACTORS C,ERQOU S,KAPTOGE S,et al.Lipoprotein(a) concentration and the risk of coronary heart disease,stroke,and nonvascular mortality[J].JAMA,2009,302(4):412-423.
[11] SOLFRIZZI V,COLACICCO A M,D'INTRONO A,et al.All-cause mortality and competing risks of fatal and nonfatal vascular events in the Italian longitudinal study on aging:impact of lipoprotein(a)[J].Rejuvenation Res,2009,12(6):395-402.
[12] van der VALK F M,BEKKERING S,KROON J,et al.Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans[J].Circulation,2016,134(8):611-624.
[13] 陈佩佩,马坤岭.低密度脂蛋白受体表达失调在靶器官损害中作用的研究进展[J].东南大学学报:医学版,2016,35(4):606-612.
[14] LEIBUNDGUT G,SCIPIONE C,YIN H,et al.Determinants of binding of oxidized phospholipids on apolipoprotein(a) and lipoprotein(a)[J].J Lipid Res,2013,54(10):2815-2830.
[15] TSIMIKAS S,WITZTUM J L.The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity[J].Curr Opin Lipidol,2008,19(4):369-377.
[16] KOTL GA D,GOB-JANOWSKA M,MASZTALEWICZ M,et al.Association between selected gene polymorphisms and statin metabolism,risk of ischemic stroke and cardiovascular disorders[J].Postepy Higieny I Medycyny Doswiadczalnej,2016,70:435.
[17] KHERA A V,EVERETT B M,CAULFIELD M P,et al.Lipoprotein(a) concentrations,rosuvastatin therapy,and residual vascular risk:an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention:an Intervention Trial Evaluating Rosuvastatin)[J].Circulation,2014,129(6):635-642.
[18] KIECHL S,WILLEIT J.The mysteries of lipoprotein(a) and cardiovascular disease revisited[J].J Am Coll Cardiol,2010,55(19):2168-2170.
[19] KAMSTRUP P R,TYBJAERG-HANSEN A,NORDESTGAARD B G.Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis[J].Arterioscler Thromb Vasc Biol,2012,32(7):1732-1741.
[20] BOS S,YAYHA R,van LENNEP J E.Latest developments in the treatment of lipoprotein(a)[J].Curr Opin Lipidol,2014,25(6):452-460.
[21] GAETA G,LANERO S,BARRA S,et al.Sex hormones and lipoprotein(a) concentration[J].Expert Opin Investig Drugs,2011,20(2):221-238.
[22] KALIAPERUMAL R,WILLIAM E,SELVAM T,et al.Relationship between Lipoprotein(a) and thyroid hormones in hypothyroid patients[J].J Clin Diagn Res,2014,8(2):37-39.
[23] SAHEBKAR A,REINER Z,SIMENTAL-MENDIA L E,et al.Effect of extended-release niacin on plasma lipoprotein(a) levels:a systematic review and meta-analysis of randomized placebo-controlled trials[J].Metabolism,2016,65(11):1664-1678.
[24] ARTEMEVA N V,SAFAROVA M S,EZHOV M V,et al.Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype[J].Atheroscler Suppl,2015,18:53-58.
[25] CIONI G,MANNINI L,LIOTTA A A,et al.Detrimental effects of niacin/laropiprant on microvascular reactivity and red cell deformability in patients with elevated lipoprotein(a) levels[J].J Thromb Thrombolysis,2016,41(3):433-435.
[26] LEEBMANN J,ROESELER E,JULIUS U,et al.Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy,lipoprotein(a)-hyperlipoproteinemia,and progressive cardiovascular disease:prospective observational multicenter study[J].Circulation,2013,128(24):2567-2576.
[27] SAFAROVA M S,EZHOV M V,AFANASIEVA O I,et al.Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography[J].Atheroscler Suppl,2013,14(1):93-99.
[28] 张洋,马坤岭.PCSK9在脂代谢调节中作用的研究进展[J].东南大学学报:医学版,2013,32(4):473-478.
[29] RAAL F J,GIUGLIANO R P,SABATINE M S,et al.Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145):a pooled analysis of more than 1,300 patients in 4 phase Ⅱ trials[J].J Am Coll Cardiol,2014,63(13):1278-1288.
[30] RAAL F J,GIUGLIANO R P,SABATINE M S,et al.PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab:an analysis of 10 clinical trials and the LDL receptor's role[J].J Lipid Res,2016,57(6):1086-1096.
[31] TSIMIKAS S,VINEY N J,HUGHES S G,et al.Antisense therapy targeting apolipoprotein(a):a randomised,double-blind,placebo-controlled phase 1 study[J].Lancet,2015,386(10002):1472-1483.
[32] BELL D A,HOOPER A J,WATTS G F,et al.Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia[J].Vasc Health Risk Manag,2012,8:651-659. |
